Trauma (Emergency, Injury, Surgery) | Preclinical Developments | UNITED STATES

Kantum Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Kantum Pharma Highlights New Research Demonstrating Beneficial Effects of P2Y14 Antagonist in Acute Kidney Injury

Lead Product(s): KB-1801

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 27, 2020

Details:

This research shows that the activation of P2Y14 receptors initiates the secretion of proinflammatory factors within the kidney and rapidly causes the recruitment of neutrophils and monocytes, starting the inflammatory cycle.

Histogen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Histogen Publishes Preclinical Data on its HST 004 Spinal Disc Program

Lead Product(s): HST 004

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 14, 2020

Details:

Clinical data from the first three cohorts of the ongoing Phase I dose-escalation trial demonstrating safety of MCY-M11 and feasibility of one-day manufacturing will be shared at the ASCO 2020.

Bone Biologics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Bone Biologics Preclinical Study Shows rhNELL-1 Effectively Promotes Bone Formation

Lead Product(s): rhNELL-1

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 08, 2020

Details:

Bone Biologics has completed a preclinical study, which shows its rhNELL-1 growth factor effectively promotes bone formation in a phylogenetically advanced spine model.

Find

Find Drugs for Trauma (Emergency, Injury, Surgery) in Preclinical Development in UNITED STATES

United States

Product Type

Companies

Kantum Pharma

Kantum Pharma Highlights New Research Demonstrating Beneficial Effects of P2Y14 Antagonist in Acute Kidney Injury

Histogen

Histogen Publishes Preclinical Data on its HST 004 Spinal Disc Program

Bone Biologics

Bone Biologics Preclinical Study Shows rhNELL-1 Effectively Promotes Bone Formation